2705, boulevard Laurier
R0-709
Québec, Québec
Canada G1V 4G2
Dernières nouvelles
Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients
Article de revueAIDS, 32 (6), 2018.
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study
Article de revueClin Infect Dis, 65 (1), 2017.
Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV
Article de revueClin Infect Dis, 64 (9), 2017.
Sofosbuvir for the treatment of hepatitis C virus infection
Article de revueCMAJ, 187 (3), 2015.
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm
Article de revueJ Infect Dis, 209 (5), 2014.
Diffusion-weighted imaging of the liver with multiple b values: effect of diffusion gradient polarity and breathing acquisition on image quality and intravoxel incoherent motion parameters--a pilot study
Article de revueRadiology, 266 (3), 2013.
Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort
Article de revueClin Infect Dis, 57 (9), 2013.
Gastrointestinal disorders in HIV including diarrhea
Chapitre de livreVolberding P (Ed.): Sande’s HIV/AIDS medicine : medical management of AIDS 2013, p. 237-248, Philadelphia, Pa.?, Elsevier / Saunders, 2012, ISBN: 9781455706952.
BI-201335. Treatment of hepatitis C virus serine protease NS3/non-structural protein 4A (NS4A) inhibitor
Article de revueDrugs Future, 37 (2), 2012.
A great time to invest in baby Boomer's hepatitis C!
Article de revueHepatology, 56 (4), 2012.
Projets actifs
- Optimiser le dépistage des populations vulnérables par goutte de sang séché, du 2022-01-15 au 2024-10-15
- Optimization of a live microneutralization assay to evaluate antibody levels against mpox in vaccinated or infected individuals in Quebec, du 2023-04-24 au 2024-04-23
Projets terminés récemment
- After the Cure: Measuring the full impacts of direct acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada, du 2022-10-01 au 2023-03-31
- Surveillance des réponses immunitaires au vaccin contre la COVID-19 chez les personnes vivant avec le VIH-1, du 2021-12-01 au 2022-11-30
- The National CIHR Hepatisis C Network (NCHCN), du 2015-04-01 au 2021-10-31